Clincosm LogoSign in Get a demo

Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality

Sponsor
Northwell Health (Other)
Overall Status
Completed
CT.gov ID
NCT00871832
Collaborator
Staten Island University Hospital (Other)
200
Enrollment
1
Location
34
Duration (Months)
5.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    To Evaluate if Pre-admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit
    Study Start Date :
    May 1, 2007
    Actual Primary Completion Date :
    Mar 1, 2010
    Actual Study Completion Date :
    Mar 1, 2010

    Outcome Measures

    Primary Outcome Measures

    1. morbidity and mortality [at time of review]

      looking to see if HbA1C correlates with morbidity (i.e. sepsis, renal failure, length of stay) or death

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older and speak English that give consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Staten Island University Hospital Staten Island New York United States 10305

    Sponsors and Collaborators

    • Northwell Health
    • Staten Island University Hospital

    Investigators

    • Principal Investigator: Mario Castellanos, MD, Staten Island University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mario Castellanos, Clinical Director of Research, Dept. of Medicine, Northwell Health
    ClinicalTrials.gov Identifier:
    NCT00871832
    Other Study ID Numbers:
    • 07-020
    First Posted:
    Mar 30, 2009
    Last Update Posted:
    Jun 6, 2013
    Last Verified:
    Jun 1, 2013
    Keywords provided by Mario Castellanos, Clinical Director of Research, Dept. of Medicine, Northwell Health
    hyperglycemia
    HgA1c
    mortality
    Additional relevant MeSH terms:
    Hyperglycemia

    Study Results

    No Results Posted as of Jun 6, 2013